BidaskClub upgraded shares of Celgene (NASDAQ:CELG) from a sell rating to a hold rating in a research note issued to investors on Friday morning, BidAskClub reports.

Other equities analysts also recently issued research reports about the company. William Blair restated a buy rating on shares of Celgene in a research note on Thursday, February 28th. Cantor Fitzgerald reaffirmed a buy rating and issued a $100.00 price target on shares of Celgene in a report on Thursday, January 31st. Mizuho set a $103.00 price target on shares of Celgene and gave the stock a buy rating in a report on Friday, April 5th. Canaccord Genuity cut shares of Celgene from a buy rating to a hold rating in a report on Thursday, January 3rd. Finally, ValuEngine raised shares of Celgene from a sell rating to a hold rating in a report on Saturday, March 30th. Twenty equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $97.37.

Shares of NASDAQ CELG opened at $96.47 on Friday. Celgene has a twelve month low of $58.59 and a twelve month high of $97.07. The company has a market capitalization of $68.33 billion, a PE ratio of 11.57, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.10. Celgene had a return on equity of 106.69% and a net margin of 30.10%. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. During the same quarter in the previous year, the business earned $2.05 EPS. The company’s revenue was up 13.8% compared to the same quarter last year. On average, analysts forecast that Celgene will post 9.85 EPS for the current fiscal year.

In other Celgene news, Director Ernest Mario bought 2,000 shares of the stock in a transaction on Tuesday, February 12th. The shares were acquired at an average price of $89.99 per share, with a total value of $179,980.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director James J. Loughlin sold 23,466 shares of the business’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the sale, the director now directly owns 62,102 shares in the company, valued at approximately $5,420,883.58. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. F3Logic LLC bought a new stake in Celgene during the 1st quarter valued at $207,000. Trillium Asset Management LLC raised its holdings in Celgene by 17.6% during the 1st quarter. Trillium Asset Management LLC now owns 209,443 shares of the biopharmaceutical company’s stock valued at $19,759,000 after acquiring an additional 31,376 shares during the period. Acima Private Wealth LLC raised its holdings in Celgene by 5.2% during the 1st quarter. Acima Private Wealth LLC now owns 3,342 shares of the biopharmaceutical company’s stock valued at $315,000 after acquiring an additional 164 shares during the period. Lee Danner & Bass Inc. raised its holdings in Celgene by 30.9% during the 1st quarter. Lee Danner & Bass Inc. now owns 24,723 shares of the biopharmaceutical company’s stock valued at $2,332,000 after acquiring an additional 5,843 shares during the period. Finally, Meridian Investment Counsel Inc. bought a new stake in Celgene during the 1st quarter valued at $282,000. 72.01% of the stock is currently owned by institutional investors and hedge funds.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What is a balanced fund?

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.